Amgen's $10B Onyx Deal Gets Antitrust Approval
Antitrust officials have approved Amgen Inc.'s $10.4 billion acquisition of Onyx Pharmaceutical Inc., the companies said Thursday, clearing the last regulatory hurdle and satisfying a major closing condition of the deal....To view the full article, register now.
Already a subscriber? Click here to view full article